BASKING RIDGE, N.J.--(BUSINESS WIRE)--April 28, 2005--Ingenix: -- New tool will help pharmaceutical companies and regulators monitor prescription drug performance -- Drug Registry will provide faster access to data to assess drug safety As the scientific community continues to develop tools to cure disease and improve the quality of life, there is increasing demand for more effective means to evaluate pharmaceutical safety. In response to this need, i3, the research services business of health care informatics leader Ingenix, is introducing i3 Aperio(TM), an advanced drug registry tool that will allow drug manufacturers and regulators to access data on the safety of newly introduced drugs faster and more efficiently than ever before. This new drug registry will pair i3’s technology and scientific expertise with the Ingenix database of de-identified health care experience and will provide faster access to data that can help researchers assess the relative risks of newly introduced drugs.
